RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, February 2025: A Hyaluronic Acid Filler, a Spine Sealant and No De Novo Grants

日本語版

February 2025 brought no De Novo grants and two original PMA approvals. One is a hyaluronic acid filler for facial wrinkles; the other is a sealant sprayed over a sutured dural repair during spine surgery.

The sealant, SpineSeal (P240027), was approved without a new clinical trial of its own, relying on clinical data from another product approved earlier. The filler, EVOLYSSE (P240022), was approved with a post-approval study that must include a set number of patients with darker skin.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 232 510(k)s in February 2025, granted 0 De Novo requests and approved 2 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

February 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayFebruary 2025January 2025February 2024
510(k)232253212
De Novo014
PMA (original)223
PMA supplement194148162

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 21 fewer than in January but above February 2024 (212). There were no De Novo grants, against 4 a year earlier, and 2 original PMAs.

The busiest product codes

February's 510(k)s spread across 155 product codes. QIH (automated radiological image processing software) led with 7, followed by DXN (system, measurement, blood-pressure, non-invasive), GEX (powered laser surgical instrument), HRS (plate, fixation, bone), IYN (system, imaging, pulsed doppler, ultrasonic) and LLZ (system, image processing, radiological) with 6 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: none

FDA granted no De Novo requests in February. De Novo grants run at a few a month, so a month with none does happen.

Original PMAs: two approvals

  • EVOLYSSE SMOOTH / EVOLYSSE FORM (P240022, Symatese): crosslinked hyaluronic acid dermal fillers with lidocaine (product code LMH)
  • SpineSeal Spine Sealant (P240027, Pramand, LLC): a sealant sprayed over a sutured dural repair in spine surgery to prevent cerebrospinal fluid leakage (NQR)

February also brought 194 PMA supplements, which cover changes to already approved PMA devices among other things.

Two devices worth a closer read

1. SpineSeal Spine Sealant (P240027, PMA). Two liquids mixed as they are sprayed form an absorbable hydrogel that seals the dural suture line. The gel resorbs in 9 to 12 weeks and is tinted blue so the coverage can be seen. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, Pramand ran no new clinical study and relied, under the six-year rule (FDAMA Section 216), on the clinical data for DuraSeal Exact Spine Sealant (P080013). The conditions of approval include a post-approval study against DuraSeal Exact, with cerebrospinal fluid leakage or pseudomeningocele within 90 days, confirmed by imaging, as the primary endpoint.

2. EVOLYSSE SMOOTH / EVOLYSSE FORM (P240022, PMA). Fillers for moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults 22 and older. The pivotal study was a randomized, double-blind, split-face comparison with Restylane-L in 140 subjects, and both products met non-inferiority on wrinkle severity at six months. The SSED notes the study was not powered for Fitzpatrick skin type subgroups. The approval order requires at least four Fitzpatrick type V and six type VI subjects to complete the post-approval study, and states that failure to comply is grounds for withdrawal of approval.

The approval order is addressed to a contact at Evolus, Inc., the U.S. correspondent, but the applicant is Symatese.

Compare the two devices

Open P240027 and P240022, star (☆) each one, tick "Compare" on both in My Workspace and press "2 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles